Further to the announcements on 29 January 2021, Braveheart Investment Group plc (AIM: BRH), is pleased to provide an update concerning progress to develop a COVID-19 test that Paraytec Limited
In the interim results for the six months ended 30 September 2020, the board of Braveheart (the “Board”) announced that it had declared the payment of a special interim dividend
Braveheart announces that on 18 November 2020, it sold a total of 112,592,405 ordinary shares in Remote Monitored System plc (“RMS”).
Braveheart announces that on 16 and 17 November 2020, it sold a total of 287,400,000 ordinary shares in Remote Monitored System plc (“RMS”) at a weighted average price of approximately
Braveheart announces that on 6 November 2020 it exercised a total of 10 million options over ordinary shares in Remote Monitored Systems plc (“RMS”) at an exercise price of 0.5p
Braveheart Investment Group (AIM: BRH) provides an update on progress with the Pharm2Farm Limited (“P2F”) anti-viral surgical mask project.
Braveheart Investment Group (AIM: BRH), is pleased to provide an update concerning progress with proof of concept for a COVID-19 test that Paraytec Limited is conducting with the University of
Braveheart Investment Group (AIM: BRH), is pleased to provide an update concerning progress with proof of concept for a COVID-19 test that Paraytec Limited is conducting with the University of
Braveheart Investment Group (AIM: BRH), is pleased to provide an operations update on Phasefocus Holdings Limited (“Phasefocus”), the computational imaging technology company in which Braveheart owns 42.67 per cent. of
Scancell to initiate development of novel DNA vaccine against COVID-19
New Media Business Created, Board Appointments and Proposed Name Change to Iconic Labs Plc
